ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer...
22 insider purchases on record · latest filing 2026-02-02.
Insiders have also filed 188 sale transactions at ALXO.